NO20082905L - Anti-IL-17 antistoff - Google Patents
Anti-IL-17 antistoffInfo
- Publication number
- NO20082905L NO20082905L NO20082905A NO20082905A NO20082905L NO 20082905 L NO20082905 L NO 20082905L NO 20082905 A NO20082905 A NO 20082905A NO 20082905 A NO20082905 A NO 20082905A NO 20082905 L NO20082905 L NO 20082905L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- human
- antibody
- immunoconjugates
- humanized
- Prior art date
Links
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Sammendrag Anti-IL-17 antistoffer bli identifisert som er karakterisert som å ha en høy affinitet og langsom av-hastighet for humant IL-17. Antistoffene i oppfinnelsen kan være kimære, humaniserte eller fullstendig humane antistoffer, immunkonjugater av antistoffene eller antigenbindende fragmenter av dem. Antistoffene i oppfinnelsen er nyttige spesielt for å behandle autoimmune, inflammatoriske, celleproliferative og utviklingslidelser.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74995305P | 2005-12-13 | 2005-12-13 | |
US80194806P | 2006-05-19 | 2006-05-19 | |
PCT/US2006/061586 WO2007070750A1 (en) | 2005-12-13 | 2006-12-05 | Anti-il-17 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20082905L true NO20082905L (no) | 2008-09-03 |
NO340827B1 NO340827B1 (no) | 2017-06-26 |
Family
ID=38008638
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082905A NO340827B1 (no) | 2005-12-13 | 2008-06-26 | Anti-IL-17-antistoffer |
NO2017044C NO2017044I1 (no) | 2005-12-13 | 2017-08-18 | iksekizumab |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2017044C NO2017044I1 (no) | 2005-12-13 | 2017-08-18 | iksekizumab |
Country Status (24)
Country | Link |
---|---|
US (2) | US7838638B2 (no) |
EP (4) | EP1963368B3 (no) |
JP (1) | JP5063612B2 (no) |
KR (1) | KR101158959B1 (no) |
CN (1) | CN101326195B9 (no) |
AU (1) | AU2006325860B2 (no) |
BR (1) | BRPI0619792B1 (no) |
CA (1) | CA2631938C (no) |
CY (3) | CY1113097T1 (no) |
DK (2) | DK1963368T6 (no) |
EA (1) | EA014298B1 (no) |
ES (2) | ES2389780T7 (no) |
HK (1) | HK1120275A1 (no) |
HR (2) | HRP20120606T4 (no) |
HU (2) | HUE039353T2 (no) |
IL (1) | IL191217A (no) |
LT (2) | LT2481753T (no) |
LU (1) | LU93189I2 (no) |
NO (2) | NO340827B1 (no) |
PL (2) | PL2481753T3 (no) |
PT (2) | PT2481753T (no) |
RS (2) | RS52509B2 (no) |
SI (2) | SI1963368T1 (no) |
WO (1) | WO2007070750A1 (no) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005051422A1 (en) | 2003-11-21 | 2005-06-09 | Celltech R & D Limited | Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
DK1963368T6 (da) * | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
AU2007226627B2 (en) | 2006-03-10 | 2012-09-20 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
EP2046835B1 (en) * | 2006-08-11 | 2011-10-26 | Schering Corporation | Antibodies to il-17a |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
NZ579594A (en) | 2007-03-12 | 2012-03-30 | Esbatech Alcon Biomed Res Unit | Sequence based engineering and optimization of single chain antibodies |
HUE027507T2 (en) * | 2007-06-25 | 2016-10-28 | Esbatech Alcon Biomed Res Unit | Procedures for Modifying Antibodies and Modified Antibodies with Improved Functional Properties |
ES2532725T3 (es) | 2007-06-25 | 2015-03-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Modificación por ingeniería genética basada en secuencia y optimización de anticuerpos de cadena sencilla |
US20110300154A1 (en) * | 2007-08-21 | 2011-12-08 | Children's Medical Center Corporation | Treatment of airway hyperreactivity |
WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
GB0807413D0 (en) * | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
JP2011519911A (ja) | 2008-05-05 | 2011-07-14 | ノヴィミュンヌ エスア | 抗il17a/il−17f交差反応抗体及びその使用方法 |
ES2493042T3 (es) * | 2008-09-29 | 2014-09-11 | Roche Glycart Ag | Anticuerpos contra la IL-17 humana y usos de los mismos |
SG2014006878A (en) * | 2008-11-12 | 2014-04-28 | Merck Sharp & Dohme | ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION |
WO2010062858A1 (en) * | 2008-11-26 | 2010-06-03 | Allergan, Inc. | Il-17 antibody inhibitor for treating dry eye |
WO2010062857A1 (en) | 2008-11-26 | 2010-06-03 | Allergan, Inc. | Klk-13 antibody inhibitor for treating dry eye |
JP5836807B2 (ja) * | 2009-03-05 | 2015-12-24 | アッヴィ・インコーポレイテッド | Il−17結合タンパク質 |
CN104974250A (zh) | 2009-05-05 | 2015-10-14 | 诺维莫尼公司 | 抗il-17f抗体及其使用方法 |
CN102905727B (zh) | 2009-10-30 | 2016-12-07 | 詹森生物科技公司 | Il-17a拮抗剂 |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
US20110293629A1 (en) * | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
BR112013002831A2 (pt) | 2010-08-05 | 2016-11-01 | Anaptysbio Inc | anticorpos direcionados contra a il-17 |
TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
SG188979A1 (en) | 2010-10-08 | 2013-05-31 | Novartis Ag | Methods of treating psoriasis using il-17 antagonists |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
LT2663577T (lt) | 2011-01-14 | 2017-07-25 | Ucb Biopharma Sprl | Antikūnas, surišantis il-17a ir il-17f |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
AU2012341081B2 (en) | 2011-11-21 | 2015-06-04 | Novartis Ag | Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles |
US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
DK2822590T3 (en) | 2012-03-07 | 2017-01-23 | Lilly Co Eli | IL-17 antibody formulation |
AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
US20150125462A1 (en) | 2012-04-20 | 2015-05-07 | Stephan Bek | Methods of treating ankylosing spondylitis using il-17 antagonists |
WO2013177101A2 (en) | 2012-05-22 | 2013-11-28 | Bristol-Myers Squibb Company | Bispecific antibodies and methods of using the same |
US9676847B2 (en) | 2012-06-25 | 2017-06-13 | Orega Biotech | IL-17 antagonist antibodies |
WO2014066726A2 (en) | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Compounds for modulating il-17 |
EP2925360A4 (en) | 2012-11-29 | 2016-07-13 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES HUMANIZED AGAINST ACTIVATED PROTEIN C AND USES THEREOF |
CU24300B1 (es) | 2013-02-08 | 2017-12-08 | Novartis Ag | Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios |
TW201444867A (zh) | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗tnf-抗il-17雙特異性抗體 |
WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US20150004133A1 (en) * | 2013-06-07 | 2015-01-01 | The Regents Of The University Of California | Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC) |
US9603882B2 (en) | 2013-08-13 | 2017-03-28 | Industrial Technology Research Institute | Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells |
US10434172B2 (en) | 2013-08-15 | 2019-10-08 | Novartis Ag | Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists |
PT3072905T (pt) * | 2013-11-18 | 2020-09-17 | Shanghai hengrui pharmaceutical co ltd | Agente de ligação a il-17a e suas utilizações |
AU2014370875B2 (en) * | 2013-12-27 | 2017-11-23 | Osaka University | Vaccine targeting IL-17A |
CA2931641C (en) * | 2013-12-30 | 2022-05-10 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
CA2937556A1 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
US11278618B2 (en) | 2014-09-10 | 2022-03-22 | Novartis Ag | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
EP3738976A1 (en) | 2015-01-12 | 2020-11-18 | Affibody AB | Il-17a-binding polypeptides |
CN107407677B (zh) | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
CN106336459B (zh) * | 2015-07-13 | 2020-12-08 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
EP3322725A1 (en) | 2015-07-16 | 2018-05-23 | Eli Lilly and Company | Treatment of pruritus |
EP4378957A2 (en) | 2015-07-29 | 2024-06-05 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
WO2017087391A1 (en) | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
CN107488227A (zh) * | 2016-06-12 | 2017-12-19 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
WO2017221174A1 (en) | 2016-06-22 | 2017-12-28 | Novartis Ag | Methods of treating vitiligo using interleukin-17 (il-17) antibodies |
WO2018015880A1 (en) | 2016-07-19 | 2018-01-25 | Novartis Ag | Methods of treating new-onset plaque type psoriasis using il-17 antagonists |
IL265350B1 (en) | 2016-09-14 | 2024-06-01 | Beijing hanmi pharm co ltd | An antibody that specifically binds to IL-17A and its functional fragment |
WO2018096467A1 (en) | 2016-11-28 | 2018-05-31 | Novartis Ag | Methods of treating acne using interleukin-17 (il-17) antagonists |
MX2019009485A (es) | 2017-02-10 | 2019-11-05 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos. |
WO2018158741A1 (en) | 2017-03-03 | 2018-09-07 | Novartis Ag | Psoriasis disease modification following long-term treatment with an il-17 antagonist |
WO2018161340A1 (en) * | 2017-03-10 | 2018-09-13 | X-Kang United Biopharmaceutical Science & Technology Co., Ltd. | Monoclonal antibody against both il-17a and il-17f and use of the same |
US10941178B2 (en) * | 2017-03-17 | 2021-03-09 | Gilead Sciences, Inc. | Method of purifying an antibody |
TW201842933A (zh) | 2017-05-05 | 2018-12-16 | 瑞士商諾華公司 | 使用il-17拮抗劑選擇性治療氣喘的方法 |
EP3641813A4 (en) | 2017-06-18 | 2021-04-21 | Kindred Biosciences, Inc. | ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE |
WO2019027828A1 (en) | 2017-08-04 | 2019-02-07 | Eli Lilly And Company | DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES |
WO2019040230A1 (en) | 2017-08-23 | 2019-02-28 | Eli Lilly And Company | TREATMENT OF GENITAL PSORIASIS |
EP3703819A1 (en) | 2017-11-02 | 2020-09-09 | Novartis AG | Method of treating tendinopathy using interleukin-17 (il-17) antagonists |
KR102048475B1 (ko) * | 2017-11-10 | 2019-11-26 | 주식회사 와이바이오로직스 | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 |
WO2019091449A1 (zh) * | 2017-11-10 | 2019-05-16 | 江苏恒瑞医药股份有限公司 | Cd96抗体、其抗原结合片段及医药用途 |
US20200277369A1 (en) | 2017-11-20 | 2020-09-03 | Novartis Ag | Method of treating hidradentitis suppurativa with il-17 antagonists |
AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
US11619832B2 (en) | 2018-03-08 | 2023-04-04 | Coopervision International Limited | Identification of contact lens wearers predisposed to contact lens discomfort |
CA3100092A1 (en) * | 2018-05-17 | 2019-11-21 | Jiangsu Qyuns Therapeutics Co., Ltd. | Anti-human interleukin 17a monoclonal antibody and application thereof |
KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
GB201810327D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
JP7504871B2 (ja) | 2018-08-29 | 2024-06-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 関節リウマチを有する対象を治療するための方法および組成物 |
WO2020064702A1 (en) | 2018-09-25 | 2020-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma |
GB201820316D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for IL-17 |
CN109369806B (zh) * | 2019-01-14 | 2019-04-19 | 迈威(上海)生物科技有限公司 | 苏金单抗制品中半胱氨酸化变异体的去除方法 |
KR20210122243A (ko) | 2019-01-31 | 2021-10-08 | 누맙 세러퓨틱스 아게 | TNFα 및 IL-17A에 대한 특이성을 가지는 다중 특이적 항체, IL-17A를 표적화하는 항체, 그리고 이의 사용 방법 |
EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
MA54861A (fr) | 2019-01-31 | 2021-12-08 | Regeneron Pharma | Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile |
PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
KR102400401B1 (ko) * | 2019-05-22 | 2022-05-24 | (주)셀인바이오 | 항염증 펩타이드 및 항염증 조성물 |
WO2021018035A1 (zh) | 2019-07-26 | 2021-02-04 | 神州细胞工程有限公司 | 人源化抗il17a抗体及其应用 |
CN114127108A (zh) | 2019-07-30 | 2022-03-01 | 江苏恒瑞医药股份有限公司 | Il-17拮抗剂治疗自身免疫疾病的方法 |
JP2022549200A (ja) | 2019-09-20 | 2022-11-24 | ノバルティス アーゲー | インターロイキン-17(il-17)アンタゴニストを使用して自己免疫疾患を治療する方法 |
CN114555792A (zh) | 2019-10-15 | 2022-05-27 | 伊莱利利公司 | 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系 |
EP4061418A1 (en) | 2019-11-19 | 2022-09-28 | Novartis AG | Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists |
IL293354A (en) | 2019-12-06 | 2022-07-01 | Novartis Ag | Methods for treating flatulence using interleukin-17 (il-17) antagonists |
GB201918558D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
GB201918557D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
WO2021123767A1 (en) | 2019-12-16 | 2021-06-24 | Bicycletx Limited | Bicyclic peptide ligands specific for il-17 |
GB201918559D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
AU2021281379A1 (en) | 2020-05-27 | 2023-02-02 | Sanofi | IL-17A modulators |
BR112022024045A2 (pt) | 2020-05-27 | 2022-12-20 | Sanofi Sa | Moduladores il-17a |
CN115812079A (zh) | 2020-06-23 | 2023-03-17 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗甲状腺眼病和格雷夫斯眼眶病的方法 |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
CN115746132B (zh) * | 2021-09-03 | 2023-09-08 | 三优生物医药(上海)有限公司 | 抗il-17a抗体及其用途 |
IT202100023816A1 (it) * | 2021-09-16 | 2023-03-16 | Takis S R L | Anticorpo contro SARS-CoV-2 e suoi usi in campo medico. |
CN113896793B (zh) * | 2021-09-30 | 2023-05-26 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
WO2023223211A1 (en) | 2022-05-16 | 2023-11-23 | Novartis Ag | Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists |
WO2023223263A1 (en) | 2022-05-18 | 2023-11-23 | Novartis Ag | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists |
WO2024121427A1 (en) | 2022-12-09 | 2024-06-13 | Sanofi | Therapeutic compounds |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US539A (en) | 1837-12-26 | Standard measurer for taking measure for coats | ||
US5225A (en) | 1847-08-07 | Latch | ||
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5612205A (en) | 1990-08-29 | 1997-03-18 | Genpharm International, Incorporated | Homologous recombination in mammalian cells |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US6274711B1 (en) | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
ATE352613T1 (de) | 1995-08-29 | 2007-02-15 | Kirin Brewery | Chimäres tier und methode zu dessen herstellung |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
EP1644416A4 (en) | 2003-06-30 | 2007-08-29 | Centocor Inc | ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
WO2005051422A1 (en) | 2003-11-21 | 2005-06-09 | Celltech R & D Limited | Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
DK1963368T6 (da) * | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
-
2006
- 2006-12-05 DK DK06846464.3T patent/DK1963368T6/da active
- 2006-12-05 EA EA200870050A patent/EA014298B1/ru active Protection Beyond IP Right Term
- 2006-12-05 SI SI200631427T patent/SI1963368T1/sl unknown
- 2006-12-05 DK DK11192240.7T patent/DK2481753T3/en active
- 2006-12-05 ES ES06846464T patent/ES2389780T7/es active Active
- 2006-12-05 EP EP06846464.3A patent/EP1963368B3/en active Active
- 2006-12-05 AU AU2006325860A patent/AU2006325860B2/en active Active
- 2006-12-05 WO PCT/US2006/061586 patent/WO2007070750A1/en active Application Filing
- 2006-12-05 ES ES11192240.7T patent/ES2672221T3/es active Active
- 2006-12-05 RS RS20120418A patent/RS52509B2/sr unknown
- 2006-12-05 EP EP11192240.7A patent/EP2481753B1/en active Active
- 2006-12-05 CN CN200680046605.8A patent/CN101326195B9/zh active Active
- 2006-12-05 PL PL11192240T patent/PL2481753T3/pl unknown
- 2006-12-05 EP EP20190492.7A patent/EP3808769A1/en active Pending
- 2006-12-05 CA CA2631938A patent/CA2631938C/en active Active
- 2006-12-05 HU HUE11192240A patent/HUE039353T2/hu unknown
- 2006-12-05 LT LTEP11192240.7T patent/LT2481753T/lt unknown
- 2006-12-05 RS RS20180601A patent/RS57255B1/sr unknown
- 2006-12-05 JP JP2008545908A patent/JP5063612B2/ja active Active
- 2006-12-05 BR BRPI0619792-2A patent/BRPI0619792B1/pt active IP Right Grant
- 2006-12-05 KR KR1020087014147A patent/KR101158959B1/ko active Protection Beyond IP Right Term
- 2006-12-05 US US12/095,398 patent/US7838638B2/en active Active
- 2006-12-05 PT PT111922407T patent/PT2481753T/pt unknown
- 2006-12-05 PT PT06846464T patent/PT1963368E/pt unknown
- 2006-12-05 SI SI200632258T patent/SI2481753T1/en unknown
- 2006-12-05 PL PL06846464T patent/PL1963368T6/pl unknown
- 2006-12-05 EP EP18160779.7A patent/EP3366702B1/en active Active
-
2008
- 2008-05-01 IL IL191217A patent/IL191217A/en active Protection Beyond IP Right Term
- 2008-06-26 NO NO20082905A patent/NO340827B1/no active Protection Beyond IP Right Term
-
2009
- 2009-02-04 HK HK09101005.2A patent/HK1120275A1/xx unknown
-
2010
- 2010-10-21 US US12/908,892 patent/US8110191B2/en active Active
-
2012
- 2012-07-23 HR HRP20120606TT patent/HRP20120606T4/hr unknown
- 2012-09-07 CY CY20121100807T patent/CY1113097T1/el unknown
-
2016
- 2016-08-24 CY CY2016030C patent/CY2016030I1/el unknown
- 2016-08-25 LT LTPA2016026C patent/LTC1963368I2/lt unknown
- 2016-08-31 LU LU93189C patent/LU93189I2/fr unknown
- 2016-09-07 HU HUS1600037C patent/HUS1600037I1/hu unknown
-
2017
- 2017-08-18 NO NO2017044C patent/NO2017044I1/no unknown
-
2018
- 2018-06-15 HR HRP20180941TT patent/HRP20180941T1/hr unknown
- 2018-06-27 CY CY20181100670T patent/CY1120365T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082905L (no) | Anti-IL-17 antistoff | |
NO20082167L (no) | Anti-Myostatin-antistoffer | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
NO20074563L (no) | Novel anti-plgf antibody | |
ATE545657T1 (de) | Tgf-beta antikörper | |
WO2020039321A8 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
EA201070695A1 (ru) | Молекулы гуманизированных антител, специфичных к il-31 | |
EA200802168A1 (ru) | Гуманизированное антитело к с-kit | |
NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
NO20084650L (no) | Modifiserte humaniserte anti-interleukin-18 antistoffer | |
WO2017004026A8 (en) | Anti-cd123 antibodies and conjugates and derivatives thereof | |
WO2014179664A3 (en) | Antibodies directed against programmed death-1 (pd-1) | |
CY1114784T1 (el) | Αντισωματα εναντι σκληροστινης | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
NO20081987L (no) | Humane, monoklonale antistoffer mot CD70 | |
ATE475672T1 (de) | Anti-il-23-antikörper | |
CY1118918T1 (el) | Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης | |
WO2012018767A3 (en) | Antibodies directed against il-17 | |
WO2014172448A3 (en) | Antibodies directed against activin receptor type ii (actrii) | |
NO20052714D0 (no) | Fremgangsmater og materialer for behandling av inflammatoriske tilstander | |
WO2015116569A3 (en) | Antibodies directed against discoidin domain receptor family, member 1 (ddr1) | |
UA98100C2 (ru) | Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его | |
UA94245C2 (en) | Anti-il-17 antibodies | |
CY1115979T1 (el) | Αντισωματα κατα της μυοστατινης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: IKSEKIZUMAB; REG. NO/DATE: EU/1/15/1085 20160509 Spc suppl protection certif: 2017044 Filing date: 20170818 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: IKSEKIZUMAB; REG. NO/DATE: EU/1/15/1085 20160509 Spc suppl protection certif: 2017044 Filing date: 20170818 Extension date: 20310428 |